Bristol Myers Squibb is embroiled in a new 203-page antitrust lawsuit filed by insurance company Cigna, alleging BMS employed illegal tactics to preserve its monopoly on the multiple myeloma drug Pomalyst. Claims center on patent fraud, misuse of the patent system, and strategic settlements that delayed generic competition, leading to supra-competitive pricing. Notably, much of the alleged misconduct relates to activities predating BMS’s acquisition of Celgene, Pomalyst’s original developer. The suit follows a similar dismissed class action, intensifying scrutiny on BMS’s practices regarding market exclusivity and patent strategies.